Shenzhen, China, 6 November 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and STOmics today jointly announced the launch of the Spatial Omics Grant program, a major research support initiative for the APAC region, including Japan, South Korea, Southeast Asia, and the Middle East. The program is designed to empower scientists and researchers in spatiotemporal omics by providing access to STOmics’ proprietary Stereo-seq technology, the world’s leading spatially-resolved, single-cell resolution transcriptomics platform.

Stereo-seq (SpaTial Enhanced REsolution Omics-Sequencing) is a powerful research solution for advanced analysis of gene expression, enabling tissue-wide spatial cell type annotation for the deeper study of cellular organization, cell-cell interaction, and spatiotemporal cellular dynamics. Identifying these characteristics has significant implications for fully investigating physiology, development, and disease.

The grant program offers valuable award packages designed to empower the scientific community. Selected winners will receive prize packages for FF/FFPE samples, ranging from Stereo-seq whole solution pilot test, significant discounts on Stereo-seq products kits, to optional DCS Cloud Advanced Analysis Package.

Furthermore, in a commitment to fostering the broader research community, all qualified applicants will receive a significant discount on STOmics products. Exclusive benefits, which are tailored to each specific region, are also available.

The program will end on Nov. 23, 2025, at 22:00 (UTC+8). All applications will be reviewed by the STOmics and MGI scientific panel based on scientific impact, novelty, feasibility, and applicability of the technology.

We encourage all researchers to visit their local application portal for detailed information on all winner awards and applicant benefits:

Japan:https://global-mgitech.com/discovery-grant-japan/

Korea: https://global-mgitech.com/discovery-grant-south-korea/

Southeast Asia: https://global-mgitech.com/stomics-mgi-spatial-discovery-grant-program-se-asia/

Middle East: https://global-mgitech.com/stomics-mgi-spatial-discovery-grant-program-middle-east/

*Grant details, benefits, and eligibility vary by region. Please refer to the specific application portal for your location for full terms and conditions.

STOmics Solutions

STOmics Solutions encompasses kits, software, and hardware, providing a powerful, robust, user-friendly end-to-end spatial omics product solution. It enables enables a “tissue-to-data” experience through in situ capturing of the whole transcriptome at nanoscale resolution and centimeter-sized field of view.

https://en.stomics.tech/col1556/index.html

About STOmics

Established in 2020, STOmics offers the most advanced spatiotemporal multi-omics platform, enabling unbiased discovery to answer biological questions in scientific research and clinical applications. Powered by Stereo-seq technology, STOmics is the only spatial technology across the globe capable of accessing the whole transcriptome at true single-cell resolution, with subcellular data achieved through Ultra-HD resolution, and field of view options over 160 square cm. In addition to several impactful publications in Cell, Nature, and Science, STOmics continues to forge international collaborations and advance scientific discoveries at a global scale.

Our commitment to delivering leading-edge spatial technologies parallels our commitment to exceptional customer experiences and support – join us in revolutionizing the field of multi-omics research with STOmics!

About MGI

MGI Tech Co., Ltd.  (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

As of September 30, 2025, MGI has a team over 2,241 employees, with research and development personnel accounting for approximately 27.04%. Our business spans over 110 countries and regions worldwide, serving more than 3,560 users.